Interleukin-15: The Molecule That Was Always There, Waiting to Be Switched On
Medical Research Archives · 03.08.2026 · 14 (7)
DOI: 10.18103/mra.2026.0466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 03.08.2026. Verfasst von P. R. Raghavan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metadichol® (nano policosanol) is a novel nanoemulsion of long-chain alcohols derived from natural food sources that has demonstrated broad immunomodulatory properties via inverse agonism of the vitamin D receptor (VDR). Its ability to modulate gene expression across diverse cancer cell lines presents a unique opportunity to explore its anticancer mechanisms through cytokine and transcription factor regulation.
Objective
This study investigated the effect of Metadichol at five concentrations (0.1 pg/mL to 100 ng/mL) on the expression of interleukin-15 (IL-15), T-box transcription factor 21 (TBET/TBX21), and Eomesodermin (EOMES) in six human cancer cell lines representing distinct tumor types: A549 (lung adenocarcinoma), FaDu (pharyngeal squamous cell carcinoma), HCT116 (colorectal carcinoma), HeLa (cervical adenocarcinoma), HepG2 (hepatocellular carcinoma), and U87MG (glioblastoma multiforme).
Methods
Quantitative gene expression analysis was performed on all six cell lines treated with Metadichol across the five concentrations described above. Fold-change values were normalized to untreated controls, and IL-15, TBET, and EOMES expression were quantified to assess dose-response relationships.
Results
IL-15 expression was consistently and significantly upregulated across all six cancer cell lines following Metadichol treatment. The most pronounced induction was observed in HCT116 cells at 1 pg/mL (4.30-fold), followed by HepG2 at 1 pg/mL (3.66-fold), HeLa at 1 ng/mL (3.04-fold), FaDu at 1 pg/mL (2.81-fold), U87MG at 1 ng/mL (2.69-fold), and A549 at 1 pg/mL (2.45-fold). TBET and EOMES exhibited variable, cell line-dependent expression patterns, with selective upregulation in certain contexts. The ultra-low effective concentrations (picogram range) are consistent with Metadichol's known mechanisms of action.
Conclusions
Metadichol potently and consistently induces IL-15 expression across multiple cancer cell types. Given IL-15's central role in activating natural killer (NK) cells, cytotoxic CD8+ T cells, memory T cells, and B cells, this finding positions Metadichol as a promising immunomodulatory compound capable of reactivating innate and adaptive antitumor immunity. The concurrent modulation of TBET and EOMES, key transcription factors governing effector lymphocyte differentiation, further supports a broad immunostimulatory mechanism. These results warrant further preclinical and clinical investigation of Metadichol as an adjunct cancer immunotherapy.
Zitieren
APA
Raghavan, P. R. (2026). Interleukin-15: The Molecule That Was Always There, Waiting to Be Switched On. Medical Research Archives, 14(7). https://doi.org/10.18103/mra.2026.0466
Vancouver
Raghavan PR. Interleukin-15: The Molecule That Was Always There, Waiting to Be Switched On. Medical Research Archives. 2026;14(7). doi:10.18103/mra.2026.0466
BibTeX
@article{Raghavan2026,
author = {Raghavan, P. R.},
title = {Interleukin-15: The Molecule That Was Always There, Waiting to Be Switched On},
journal = {Medical Research Archives},
year = {2026},
volume = {14},
number = {7},
doi = {10.18103/mra.2026.0466}
}
EUVIMED